Harvard Bioscience Inc HBIO
We take great care to ensure that the data presented and summarized in this overview for HARVARD BIOSCIENCE INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HBIO
View all-
Black Rock Inc. New York, NY2.84MShares$5.97 Million0.0% of portfolio
-
Punch & Associates Investment Management, Inc. Edina, MN2.77MShares$5.82 Million0.44% of portfolio
-
Harvey Partners, LLC Tarrytown, NY2.72MShares$5.7 Million0.87% of portfolio
-
Amh Equity LTD2.39MShares$5.02 Million8.88% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.15MShares$4.52 Million0.0% of portfolio
-
Granahan Investment Management, LLC Waltham, MA1.87MShares$3.92 Million0.21% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.72MShares$3.6 Million0.0% of portfolio
-
B. Riley Asset Management, LLC Dallas, TX1.54MShares$3.23 Million2.43% of portfolio
-
Royce & Associates LP1.45MShares$3.05 Million0.04% of portfolio
-
Boothbay Fund Management, LLC New York, NY1.34MShares$2.81 Million0.1% of portfolio
Latest Institutional Activity in HBIO
Top Purchases
Top Sells
About HBIO
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.
Insider Transactions at HBIO
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 13
2024
|
James W Green Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+0.32%
|
$20,000
$2.91 P/Share
|
Jun 06
2024
|
James W Green Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+0.64%
|
$60,000
$3.07 P/Share
|
May 21
2024
|
Thomas W Loewald Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,872
+13.45%
|
-
|
May 21
2024
|
Bertrand Loy Director |
BUY
Grant, award, or other acquisition
|
Direct |
56,575
+50.0%
|
-
|
May 21
2024
|
Alan I Edrick Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,872
+14.34%
|
-
|
May 21
2024
|
Katherine A. Eade Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,872
+12.85%
|
-
|
Mar 06
2024
|
Jennifer Cote Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,920
-5.55%
|
$39,680
$4.11 P/Share
|
Mar 05
2024
|
James W Green Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
429,594
+6.74%
|
-
|
Mar 05
2024
|
Jennifer Cote Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
71,600
+18.37%
|
-
|
Dec 31
2023
|
James W Green Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
82,790
-3.03%
|
$413,950
$5.35 P/Share
|
Dec 29
2023
|
Jennifer Cote Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,910
-2.65%
|
$29,550
$5.35 P/Share
|
Dec 29
2023
|
James W Green Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
128,392
-1.14%
|
$641,960
$5.35 P/Share
|
Aug 17
2023
|
James W Green Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
25,000
+0.87%
|
$100,000
$4.38 P/Share
|
Jun 11
2023
|
James W Green Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
48,373
-1.68%
|
$241,865
$5.46 P/Share
|
May 22
2023
|
Alan I Edrick Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,554
+10.08%
|
-
|
May 22
2023
|
Thomas W Loewald Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,554
+9.29%
|
-
|
May 22
2023
|
Katherine A. Eade Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,554
+8.79%
|
-
|
May 22
2023
|
Bertrand Loy Director |
BUY
Grant, award, or other acquisition
|
Direct |
31,516
+28.51%
|
-
|
Mar 15
2023
|
Alan I Edrick Director |
BUY
Open market or private purchase
|
Direct |
16,192
+7.4%
|
$32,384
$2.62 P/Share
|
Mar 15
2023
|
James W Green Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+0.69%
|
$40,000
$2.6 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 695K shares |
---|---|
Open market or private purchase | 30K shares |
Payment of exercise price or tax liability | 227K shares |
---|